b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30768980</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>09</Month>\n            <Day>09</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>09</Month>\n            <Day>09</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1879-0712</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>853</Volume>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Jun</Month>\n                        <Day>15</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>European journal of pharmacology</Title>\n                <ISOAbbreviation>Eur. J. Pharmacol.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>\xce\xb1<sub>1D</sub>-adrenoceptor involves the relaxation effect of farrerol in rat aortic vascular smooth muscle cells.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>169-183</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S0014-2999(19)30103-7</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejphar.2019.02.012</ELocationID>\n            <Abstract>\n                <AbstractText>The aim of this study was to investigate the relaxation effect of farrerol on rat aortic vascular smooth muscle cells (VSMCs) and its underlying mechanism. VSMCs were cultured primarily and were used to examine the relaxation effect of farrerol. Cells surface and length were measured by dynamic observation, or by rhodamine-phalloidin labeling and hematoxylin-eosin staining. Cells contractive activity were tested using collagen gel contraction assay. The [Ca<sup>2+</sup>]<sub>in</sub> was measured with molecular probe fluo-4-AM. The mRNA and protein expression of regulatory proteins for contraction were measured. In addition, rat aortic VSMCs were transfected with lentivirus-mediated \xce\xb1<sub>1D</sub>-adrenoceptor gene-shRNA, then the effect of farrerol were detected by the above experimental methods. The results revealed that 10 \xce\xbc\xce\x9c Ang\xe2\x85\xa1 promoted cell contraction, increased [Ca<sup>2+</sup>]<sub>in</sub> and enhanced collagen contraction in rat aortic VSMCs. 10 \xce\xbc\xce\x9c Ang\xe2\x85\xa1 not only increased expression of myosin light chain kinase (MLCK) and smooth muscle protein 22\xce\xb1 (SM22\xce\xb1), but also increased phosphorylation level of myosin light chain (MLC) and myosin phosphatase target subunit 1 (MYPT1). The above effects induced by Ang\xe2\x85\xa1 could be significantly inhibited by farrerol in a concentration dependent manner. When the cells were transfected with lentivirus mediated \xce\xb1<sub>1D</sub>-adrenoceptor gene-shRNA, the effects of farrerol on changes induced by Ang\xe2\x85\xa1 in rat aortic VSMCs were markedly reversed. In conclusion, farrerol could produce relaxtion effect in rat aortic VSMCs precontracted by 10 \xce\xbc\xce\x9c Ang\xe2\x85\xa1, which was involved in downregulation expression of MLCK and SM22\xce\xb1, and inhibition phosphorylation level of MYPT1 and MLC via activating \xce\xb1<sub>1D</sub>-adrenoceptor gene.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2019. Published by Elsevier B.V.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Qin</LastName>\n                    <ForeName>Xiaojiang</ForeName>\n                    <Initials>X</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>School of Public Health, Shanxi Medical University, No. 56, Xinjian South Road, Taiyuan 030001, Shanxi Province, China; Shanxi University of Chinese medicine, No. 121, Daxuejie, Jinzhong 030619, Shanxi Province, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hou</LastName>\n                    <ForeName>Xiaomin</ForeName>\n                    <Initials>X</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology, Shanxi Medical University, No. 56, Xinjian South Road, Taiyuan 030001, Shanxi Province, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhang</LastName>\n                    <ForeName>Kun</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>School of Pharmaceutical Science, Shanxi Medical University, No. 56, Xinjian South Road, Taiyuan 030001, Shanxi Province, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Li</LastName>\n                    <ForeName>Qingshan</ForeName>\n                    <Initials>Q</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Shanxi University of Chinese medicine, No. 121, Daxuejie, Jinzhong 030619, Shanxi Province, China; School of Pharmaceutical Science, Shanxi Medical University, No. 56, Xinjian South Road, Taiyuan 030001, Shanxi Province, China. Electronic address: sxykdxyxy@163.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>02</Month>\n                <Day>12</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Netherlands</Country>\n            <MedlineTA>Eur J Pharmacol</MedlineTA>\n            <NlmUniqueID>1254354</NlmUniqueID>\n            <ISSNLinking>0014-2999</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D002867">Chromones</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D018340">Receptors, Adrenergic, alpha-1</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>11128-99-7</RegistryNumber>\n                <NameOfSubstance UI="D000804">Angiotensin II</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>24211-30-1</RegistryNumber>\n                <NameOfSubstance UI="C015881">farrerol</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 3.1.3.16</RegistryNumber>\n                <NameOfSubstance UI="C499850">Ppp1r12a protein, rat</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 3.1.3.16</RegistryNumber>\n                <NameOfSubstance UI="D054645">Protein Phosphatase 1</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000804" MajorTopicYN="N">Angiotensin II</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001011" MajorTopicYN="N">Aorta</DescriptorName>\n                <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>\n                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>\n                <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002867" MajorTopicYN="N">Chromones</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009131" MajorTopicYN="N">Muscle, Smooth, Vascular</DescriptorName>\n                <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D054645" MajorTopicYN="N">Protein Phosphatase 1</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018340" MajorTopicYN="N">Receptors, Adrenergic, alpha-1</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014661" MajorTopicYN="N">Vasoconstriction</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014664" MajorTopicYN="N">Vasodilation</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Farrerol</Keyword>\n            <Keyword MajorTopicYN="N">Rat aorta</Keyword>\n            <Keyword MajorTopicYN="N">Relaxation</Keyword>\n            <Keyword MajorTopicYN="N">Vascular smooth muscle cells</Keyword>\n            <Keyword MajorTopicYN="N">\xce\xb1(1D)- adrenoceptor</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>09</Month>\n                <Day>04</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2019</Year>\n                <Month>01</Month>\n                <Day>31</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>02</Month>\n                <Day>11</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>2</Month>\n                <Day>16</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>9</Month>\n                <Day>10</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>2</Month>\n                <Day>16</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30768980</ArticleId>\n            <ArticleId IdType="pii">S0014-2999(19)30103-7</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.ejphar.2019.02.012</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'